TFS Trial Form Support
TFS HealthScience is a global mid-size Contract Research Organization, wholly owned by Ratos since 2019, that delivers Phase I–IV clinical development, real-world evidence, FSP outsourcing, and strategic resourcing to biotech and pharma sponsors across five therapeutic specialties: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology.
- Company typePrivate
- Founded1996
- HeadquartersLund, Sweden
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What TFS Trial Form Support does
TFS HealthScience (legally TFS Trial Form Support AB) is a privately held, full-service global Contract Research Organization founded in 1996 in Lund, Sweden, and wholly owned by Swedish private equity firm Ratos since 2019. With nearly 700 professionals operating across 50 countries and 24+ owned offices spanning North America, Europe, the Middle East, and Asia-Pacific, TFS delivers Phase I–IV clinical development, real-world evidence studies, functional service provider (FSP) outsourcing, and strategic resourcing solutions to biotech and pharmaceutical sponsors. Its core products include Clinical Development Services, the TFS ReAL (Real World Evidence) platform, the TFS-RWE Algorithm for protocol optimization, and Strategic Resourcing Solutions spanning single-resource insourcing to fully managed teams; these are organized around five therapeutic specialties: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology.
The technology stack integrates an EDC/CTMS/eTMF clinical trial management platform with AI-driven patient targeting, decentralized trial capabilities (eConsent, ePRO/eDiary, eVisits, wearables), and proprietary RWE analytics combining structured data ML with NLP for unstructured records. Therapeutic track record is material to credibility: 400+ dermatology trials, 350+ internal medicine trials, 300+ oncology trials, 140+ neuroscience trials, 70+ ophthalmology trials, and 250+ RWE/Phase IV studies, executed across 8,000+ trial sites and enrolling more than 300,000 patients cumulatively.
TFS makes money through professional services and managed services contracts priced on a quote-based, custom engagement model tailored to each sponsor's therapeutic area, study complexity, and scope of services; pricing is not publicly disclosed. Distribution is exclusively direct enterprise field sales, augmented by event-driven demand generation at ESMO, EADV, AAO, ARVO, CNS Summit, and related conferences, with digital content marketing and a global investigator database as community-building assets. The company has executed six strategic acquisitions since 2005 (most recently Appletree CI Group in 2023) and formalized a 2026 partnership with VERIGRAFT on an Advanced Therapy Medicinal Product trial.
TFS Trial Form Support firmographics
Firmographics- Name
- TFS Trial Form Support
- Legal name
- TFS Trial Form Support AB Group
- Website
- https://tfscro.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- TFS HealthScience is a global mid-size Contract Research Organization, wholly owned by Ratos since 2019, that delivers Phase I–IV clinical development, real-world evidence, FSP outsourcing, and strategic resourcing to biotech and pharma sponsors across five therapeutic specialties: Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology.
- Ownership category
- akta.pro rank
Where TFS Trial Form Support is headquartered
LocationHeadquarters
- HQ city
- Lund
- HQ country
- Sweden
- HQ region
- Europe
Offices24 records
Markets served
TFS Trial Form Support business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical Development Services: Full-service Phase I-III and Phase IV/Real World Evidence clinical trial management for biotech and pharmaceutical sponsors. Covers regulatory strategy, clinical operations, site management, data management, biostatistics, medical writing, drug safety, and quality compliance.
- Functional Services (FSP): Fit-for-purpose FSP outsourcing models providing embedded or dedicated teams for specific clinical functions (project management, regulatory, clinical monitoring, data management, medical writing, drug safety, quality). Delivered through flexible pricing models scaling from single service to full functional outsourcing.
- Strategic Resourcing Solutions: Flexible staffing and recruitment services providing individual talent experts or entire managed teams. Includes professional insourcing (short- and long-term) and permanent recruitment services across all clinical development functions and seniority levels.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels8 records
TFS Trial Form Support product offering
Product offeringCore offering
TFS HealthScience (legal entity: TFS Trial Form Support AB) is a global mid-size Contract Research Organization (CRO) that delivers full-service clinical development solutions, functional service provider (FSP) outsourcing models, and strategic resourcing services to biotech and pharmaceutical sponsors. The company operates across Phase I–IV and real-world evidence studies, supported by proprietary platforms including TFS ReAL for RWE and integrated CTMS/EDC/eTMF systems, with therapeutic specialization in dermatology, internal medicine, neuroscience, oncology, and ophthalmology.
Product overview
TFS HealthScience is a full-service global Contract Research Organization (CRO) offering a unified platform of clinical development and resourcing solutions. The core portfolio centers on Clinical Development Services combined with Functional Services (FSP) and Strategic Resourcing Solutions, supported by specialized Therapeutic Area CRO Services in Dermatology, Internal Medicine, Neuroscience, Oncology, and Ophthalmology. Key product lines include TFS ReAL (Real World Evidence platform) for late-phase and RWE studies, investigator database for site network management, and Phase I-IV clinical trial services. The company operates with nearly 700 professionals across 50 countries, delivering tailored solutions from early-phase planning through post-authorization studies.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Development Services Full-service clinical development solutions covering regulatory strategy, clinical operations, Phase I–III trials, and post-authorization studies with scientific and operational expertise tailored to project needs. Targeted at biotech and pharmaceutical sponsors across five core therapeutic areas.
- Functional Services (FSP) Fit-for-purpose FSP outsourcing models for clinical workforce management, ranging from global end-to-end development to single services, with embedded team approach and flexible pricing.
- Strategic Resourcing Solutions
Quantifiable outcome
- 400+ completed dermatology clinical trials with 85,000+ patients across 8,000+ sites
- +6 more outcomes
Companies that use TFS Trial Form Support
Customer profileNamed customers1 record
Segments7 records
Ideal customer profiles2 records
TFS Trial Form Support technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability7 records
Feature6 records
TFS Trial Form Support partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, minor and strategic.
- VERIGRAFTcoreTFS HealthScience and VERIGRAFT partnered on the pivotal Phase II/III trial of P-TEV (personalized tissue-engineered vein) for chronic venous insufficiency (CVI). TFS provides full-service CRO support including regulatory navigation, site management, clinical operations, and operational expertise for this advanced therapy medicinal product (ATMP). The trial is designed to evaluate the safety, functionality, and long-term performance of the personalized tissue-engineered vein graft in patients with failing deep venous valves.
- Appletree CI GroupcoreTFS acquired Swiss-based Appletree CI Group in 2023, expanding its expertise in ophthalmology and medical devices. This acquisition strengthened TFS's capabilities in eye health clinical development and broadened its therapeutic portfolio.
- GCP Clinical Studies (Israel)minorTFS formalized its agreement with GCP Clinical Studies in Israel in 2023, expanding its footprint in the Israeli market through an established local partner.
- Duke Clinical Research Institute (DCRI)strategicTFS partnered with DCRI to provide data management solutions across the academic research organization's study portfolio, integrating TFS's data management expertise with DCRI's academic research capabilities.
- VeevastrategicTFS partnered with Veeva to offer a safety database solution for its clinical trials, integrating Veeva's safety technology platform into TFS's service offering.
- Medidata (Rave EDC)strategicTFS joined the Medidata Partner Program with Rave EDC accreditation, enabling TFS to leverage Medidata's electronic data capture platform for client clinical trials.
- SCIdermcoreTFS acquired SCIderm, a dermatology specialist CRO, in 2016, expanding its operations in Germany and deepening its therapeutic expertise in dermatology clinical research.
- Beardsworth Consulting Group (US)coreTFS acquired Beardsworth Consulting Group in the US, an oncology and vaccine niche CRO, strengthening TFS's oncology and vaccine capabilities.
- Dimensione Ricerca S.r.l (Italy)coreTFS acquired Dimensione Ricerca S.r.l, the first established CRO in Italy, expanding its European footprint and adding Italian regulatory and clinical operations expertise.
- IMRO-TRAMARKO (Netherlands)coreTFS acquired IMRO-TRAMARKO, the first established CRO in the Netherlands, expanding operations to Benelux and Germany.
- CDC Clinical Data CarecoreTFS acquired CDC Clinical Data Care in 2005 to strengthen regulatory, pharmacovigilance, and medical writing services, also expanding into Spain through the acquisition of Clinical Data Care, Spain.
Scale indicators16 records
Recent moves9 records
Expansion highlights6 records
TFS Trial Form Support competitors and assessment
Company assessmentDirect peers
- Medpace: US-based mid-size full-service CRO with comparable therapeutic specialization and biotech/pharma focus. Closely comparable business model and target customer base, but larger and US-public, illustrating both the bull and scale-gap cases for TFS.
- Syneos Health: Large biopharmaceutical solutions organization combining CRO services with commercial. Direct overlap on clinical development and FSP/resourcing, and competitor for biotech sponsors at the upper-mid end of the market.
- Worldwide Clinical Trials: Mid-size global CRO focused on complex therapeutic areas including neuroscience, oncology, and rare disease — directly comparable therapeutic mix and biotech sponsor overlap with TFS.
Broad incumbents
- Parexel: Large global CRO with full-service clinical development, FSP, and biopharma services. Comparable in offering breadth and biotech/pharma customer overlap, but at materially greater scale following EQT/GS take-private.
- ICON plc: Top-tier global CRO offering full-service clinical development, FSP, labs, and post-approval services. Major scale competitor that can match TFS across the full funnel and pressures mid-size players on large programs.
- Fortrea (formerly LabCorp Drug Development / Covance): Mid-large full-service CRO spun out of LabCorp in 2023. Closely comparable service portfolio across clinical development, FSP, and resourcing, and a key scale competitor for mid-size CRO opportunities.
- IQVIA: Largest global CRO/biopharma services platform with unmatched data, technology, and operational scale. Sets the upper-bound ceiling on what TFS can competitively bid for in mega-trial mandates.
- Charles River Laboratories: Global CRO/nonclinical discovery and safety assessment provider with growing clinical services footprint. Comparable customer base in biotech/pharma, with deeper upstream discovery integration than TFS.
Regional players
- KCR CRO: European-headquartered mid-size CRO with comparable therapeutic specialization (oncology, dermatology, rare disease) and biotech sponsor focus. Direct regional peer in Europe and a comparable scale benchmark.
Emerging players
- Caidya (formerly dMed / Clinipace): Mid-size global CRO with strong Asia-Pacific and US presence, focused on biotech sponsors. Comparable therapeutic breadth and biotech customer overlap, and an active consolidator in the mid-size segment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
TFS Trial Form Support social profiles
Digital presenceTFS Trial Form Support compliance and trust
Trust signalCompliance6 records
TFS Trial Form Support financial estimates
Financial estimateRevenue estimate
Valuation estimate
TFS Trial Form Support leadership team
Management profileNumber of profiles
Profiles10 records
TFS Trial Form Support subsidiaries and ownership
Company hierarchySubsidiaries6 records
TFS Trial Form Support funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TFS Trial Form Support M&A and investment
M&A and investmentM&A1 record
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TFS Trial Form Support
What does TFS Trial Form Support do?
TFS HealthScience (legal entity: TFS Trial Form Support AB) is a global mid-size Contract Research Organization (CRO) that delivers full-service clinical development solutions, functional service provider (FSP) outsourcing models, and strategic resourcing services to biotech and pharmaceutical sponsors. The company operates across Phase I–IV and real-world evidence studies, supported by proprietary platforms including TFS ReAL for RWE and integrated CTMS/EDC/eTMF systems, with therapeutic specialization in dermatology, internal medicine, neuroscience, oncology, and ophthalmology.
Is TFS Trial Form Support a public or private company?
TFS Trial Form Support is a private company. It is classified as private equity controlled and is currently operating.
When was TFS Trial Form Support founded?
TFS Trial Form Support was founded in 1996. It employs 501 to 1,000 people.
Where is TFS Trial Form Support based?
TFS Trial Form Support is headquartered in Lund, Sweden, in the Europe region.
How does TFS Trial Form Support make money?
Three revenue lines are on record. Clinical Development Services are the primary driver. The others are functional Services (FSP) and strategic Resourcing Solutions.
Who are TFS Trial Form Support's main competitors?
Direct peers on record are Medpace, Syneos Health and Worldwide Clinical Trials. Broad incumbents are Parexel, ICON plc, Fortrea (formerly LabCorp Drug Development / Covance), IQVIA and Charles River Laboratories. KCR CRO is listed as a regional player. Caidya (formerly dMed / Clinipace) is listed as an emerging player.
Does TFS Trial Form Support have an API?
No public API is recorded for TFS Trial Form Support.